Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

SA Transcripts 161.49K Followers Follow Syndax Pharmaceuticals, Inc. ( SNDX ) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDT Company Participants Sharon Klahre - Vice President of Investor Relations & Communications Michael Metzger - CEO & Director Steven Closter - Chief Commercial Officer Nicholas Botwood Keith Goldan - CFO, Treasurer & Principal Accounting Officer Conference Call Participants Bradley Canino - Guggenheim Securities, LLC, Research Division Faisal Khurshid - Jefferies LLC, Research Division Philip Nadeau - TD Cowen, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Etzer Darout - Barclays Bank PLC, Research Division David Dai Salim Syed - Mizuho Securities USA LLC, Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Mayank Mamtani - B. Riley Securities, Inc., Research Division Presentation Operator Good day, everyone, and welcome to the Syndax Second Quarter 2026 Earnings Conference Call. Today's call is being recorded. [Operator Instructions] At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals. Sharon Klahre Vice President of Investor Relations & Communications Great. Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's Second Quarter 2026 Financial and Operating Results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Steve Closter, Chief Commercial Officer; Dr. Nick Botwood, Head of R&D and Chief Medical Officer; and Keith Goldan, Chief Financial Officer. This call is accompanied by a slide deck that has been posted on the Investor page of the company's website. You can now turn to our forward-looking statements on Slide 2. Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform